Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIM(SM) registry was established to collect and analyze data for...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Immunother
Asıl Yazarlar: Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099373/
https://ncbi.nlm.nih.gov/pubmed/27714434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1910-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller